Literature DB >> 3721930

Local control and survival of breast cancer treated by limited surgery followed by irradiation.

R Calle, J R Vilcoq, B Zafrani, P Vielh, A Fourquet.   

Abstract

Between 1960 and 1978, 324 patients with early breast cancer were treated by lumpectomy with or without axillary dissection followed by radiation therapy. All were followed for a minimum of 5 years. All patients were, retrospectively, classified T1, T2, N0, N1a, in the TNM (U.I.C.C.) Classification. The retrospective analysis of the local-regional patterns of failure revealed that young age (less than or equal to 32 years) and premenopausal status were associated with an increased rate of local failure, whereas tumor size and location showed no influence. No pathological features were associated with an increased risk of local recurrence, whether pathological subtypes, Scarff Bloom and Richardson grading, intraductal associated component, or vascular involvement. The absolute 5 year disease-free survival rate was 87% in patients who recurred and 93% in those who did not. The absolute 10 year disease-free survival rates were 75 and 82%, respectively. Therefore, these results confirm that loco-regional failure does not significantly influence the disease-free survival.

Entities:  

Mesh:

Year:  1986        PMID: 3721930     DOI: 10.1016/0360-3016(86)90379-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Audit of local recurrence following breast conservation surgery with 5-mm target margin and hypofractionated 40-Gray breast radiotherapy for invasive breast cancer.

Authors:  Siong-Seng Liau; Massimiliano Cariati; David Noble; Charles Wilson; Gordon C Wishart
Journal:  Ann R Coll Surg Engl       Date:  2010-06-01       Impact factor: 1.891

2.  Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base.

Authors:  S Eva Singletary; Lina Patel-Parekh; Kirby I Bland
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

3.  Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients.

Authors:  Ali Arab Kheradmand; Neda Ranjbarnovin; Zahra Khazaeipour
Journal:  World J Surg Oncol       Date:  2010-04-17       Impact factor: 2.754

4.  Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care.

Authors:  L K Temple; E E Wang; R S McLeod
Journal:  CMAJ       Date:  1999-10-19       Impact factor: 8.262

5.  Pathological features of invasive breast cancer associated with a high risk of local recurrence after tumour excision and radical radiotherapy.

Authors:  A S Bulman; R P Lindley; P Parsons; H Ellis
Journal:  Ann R Coll Surg Engl       Date:  1988-09       Impact factor: 1.891

Review 6.  Radiation therapy for early breast cancer.

Authors:  Georgios Koukourakis
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

7.  Long-term results of breast conservation therapy for breast cancer.

Authors:  P T Neff; H D Bear; C V Pierce; M M Grimes; M D Fleming; J P Neifeld; D Arthur; J S Horsley; W Lawrence; M J Kornstein
Journal:  Ann Surg       Date:  1996-06       Impact factor: 12.969

Review 8.  Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy.

Authors:  M S Anscher; P Jones; L R Prosnitz; W Blackstock; M Hebert; R Reddick; A Tucker; R Dodge; G Leight; J D Iglehart
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

9.  Multiple margin positivity of frozen section is an independent risk factor for local recurrence in breast-conserving surgery.

Authors:  Jeeyeon Lee; Seokwon Lee; Youngtae Bae
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

Review 10.  [Is axillary dissection in clinically lymph node-negative breast carcinoma further indicated?].

Authors:  F K Böhler; H Eiter; W Rhomberg
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.